Estrogen receptor expression in breast cancer: We cannot ignore the shades of gray

American Journal of Clinical Pathology

Volumn 130, Issue 6, 2008, Pages 853-854

  Allison, Kimberly H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; EDITORIAL; FALSE NEGATIVE RESULT; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN;

EID: 58049216738     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCP3P3XHTCYGZIA     Document Type: Editorial

References (14)

1. Gomez-Fernandez C, Daneshbod Y, Nassiri M, et al. Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. Am J Clin Pathol. 2008;130:879-882.
2. Hodi Z, Chakrabarti J, Lee AHS, et al. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. J Clin Pathol. 2007;60:299-302.
3. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol. 2005;23:148-154.
4. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003;120:86-92.
5. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005;12:16-20.
6. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol. 2005;123:21-27.
7. Swanson PE, Schmidt RA. Beneath the surface of the mud, part II: the dichotomization of continuous biologic variables by maximizing immunohistochemical method sensitivity. Am J Clin Pathol. 2005;123:9-12.
8. Allred CD, Mohsin SK. ER expression is not bimodal in breast cancer. Am J Clin Pathol. 2005;124:474-476.
9. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
10. Badve SS, Baehner FL, Gray RP, et al. Estrogen and progesterone receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcriptase polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26:2473-2481.
11. Grimes R, Saiz E, Sanchez B, et al. Successful design of a low-level estrogen receptor positive tissue controls for critical quality control measures [abstract]. Mod Pathol. 2008;1:34A.
12. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol. 2007;25:118-145.
13. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4(suppl 3):S1-S22.
14. Yaziji H, Taylor CR, Goldstein NS, et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. In press.